> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Moving Animal Antimicrobials to Rx-only
- URL: https://www.fdaweb.com/guide-on-moving-animal-antimicrobials-to-rx-only/
- Published: 2019-09-23T12:00:00.000Z
- Updated: 2026-09-15T01:51:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145063

FDA has posted a draft [Guidance](http://email.prnewswire.com/wf/click?upn=zySGXW1QLHU8t7wSbPI8iADmwAaKTbie2jeFmcdktodWslYXM7YsatWIyhJo525QziT-2BXLjNK8rMwuTsyuaLWEAex7kB1ojMUTe2Hp4VWqXVby0kAHNSM1c7LbAbye-2By-2BkxhhMuM1O2hbxsiuhHri-2BzHFQMepeBsTpDdtQSloPBcLZC-2FiVEEtnUDdyPq97TaBFl-2FwFuAmgdSWMUOZLze0BbFHBmObhRPCu-2BnQptBiAV4rANcs8YhJlT-2Bbvu6zyD5u0yqzUIgglPovoWhNFk-2B2tZuainfaTvvcJVvYvDbaKsu-2BqAtJhnE3iH1X2G-2BfQLMu1TMHfpCkQJkL-2BbcTjzfcuBVB-2FSatSEtZo9hV57wz-2Fo-3D%5F0rSs0MUd8rrc2bLt3BTQPwZCt9F-2Bz5z7s5bI9ZMdFWUg8ZPQKgPNAxSxXPqT4fycGvNMN8KZw-2BrUkMt5PfsEJD-2BNf7ZUl9xy3b13vuQKo02c8p-2FcMkgnvXrB8NXI3sCi1UCEyLP8672-2FgG7p3g6-2BZWno5JEWw70ndE0dW5q5I4tAzCDJffakV7GbgCUzql-2FtzaGeU55Lb0z2RAUKRNhOn04kNMTF7KZn2C7HXLegxFVSMKKIgn2c4-2B4CCEDVj4Vq5D0KjJzecnyUNyrWz0L8XmrKXIz22tlDbyhmfJu9JPX9phbSUfTzMEfY9quXNMfUaDIpJFZiG8JBlpkcabEVaWNPhNqsmWZDZBCmHiVfiYY-3D&ref=fdaweb.com) for Industry (GFI) #263, “Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter,” to help explain the recommended process for voluntarily changing the approved marketing status of approved animal-use antimicrobials from over-the-counter to prescription-only. The document is part of [FDA's Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings](http://email.prnewswire.com/wf/click?upn=zySGXW1QLHU8t7wSbPI8iADmwAaKTbie2jeFmcdktodWslYXM7YsatWIyhJo525QDtIMmPg4qz-2B7-2BbLKDSTPz6bQfLhNdgyMMIFrzDz8lHWrqLIFDMhBvuLKBh-2FJNRRyVXyfG9ViA4ZbwvcLamKPSQ-2BhoOXrQWfhq3PIxy8EllrXVyxKxYUfY1tlM-2F9YQ91iG-2BMY8FP361RcVyy-2FZbHFHtUH9TFrAvajpC-2FrtfF2X-2FJNgT2-2BMKk7gjvf6Pk9dWzX4ey4G9JwjDev6Cwqd6k6gL2gOKavXNhaycjwLgVoapE-3D%5F0rSs0MUd8rrc2bLt3BTQPwZCt9F-2Bz5z7s5bI9ZMdFWUg8ZPQKgPNAxSxXPqT4fycGvNMN8KZw-2BrUkMt5PfsEJD-2BNf7ZUl9xy3b13vuQKo02c8p-2FcMkgnvXrB8NXI3sCi1UCEyLP8672-2FgG7p3g6-2BZWno5JEWw70ndE0dW5q5I4tAzCDJffakV7GbgCUzql-2FtzaGeU55Lb0z2RAUKRNhOnxWpwlhZmMCgZrHM98XhynhhtoxRQBk3z2HmK-2FzqwRW0GWhkesxAf4X5fWv3ROHrMqpOEZBLYl3teAxTgFiXSQ513Or53vj-2FBrsr-2FQtux7wLZk7WFH2vJO8FIS6t0zsgVj4SVXkOmgLO6g5ma6AMcms-3D&ref=fdaweb.com) and is intended to build on the momentum generated by the [successful implementation of GFI #213](http://email.prnewswire.com/wf/click?upn=zySGXW1QLHU8t7wSbPI8iADmwAaKTbie2jeFmcdktodWslYXM7YsatWIyhJo525QkBh58OYUf0onXMW7HRZsjDO7NPv7oMsrIiiAlC7Gwac70Yp5szMsey14499-2Bg7Iij5T7KUUGYECtVpKMCREMdTsD0rtZGCd-2B5P8tT7ui1JleGMLLVURWQygR-2B-2BhdiP6F5E60yqXwQnnHkW7wemCLIHbnR3yEZ-2BtlUAs-2BoR-2Br-2FyY9U-2B-2FS-2Bj6ThXjgKCwwwRn32DDkpsgnfbpXlRRKn66SlTdlZIVaZ3fA-2FkBG-2BzdFZ2BNuChX6AsUK4ZvC6oMHG3jG34es92Y8mGEXeHHLfXEOAURQ1FesZUFI2pM2gsALgw-3D%5F0rSs0MUd8rrc2bLt3BTQPwZCt9F-2Bz5z7s5bI9ZMdFWUg8ZPQKgPNAxSxXPqT4fycGvNMN8KZw-2BrUkMt5PfsEJD-2BNf7ZUl9xy3b13vuQKo02c8p-2FcMkgnvXrB8NXI3sCi1UCEyLP8672-2FgG7p3g6-2BZWno5JEWw70ndE0dW5q5I4tAzCDJffakV7GbgCUzql-2FtzaGeU55Lb0z2RAUKRNhOnwRoF7J4Rd34WR5zDYy88l2wclZyvHBoa9XHUFCPRS3-2FhthClzE0rP4ZEvecCF17LZwM1Jc-2FVSQA977KNEzcKhdE1a1-2BhYvbfLPC5-2BMWopQ7m0-2F9Y7TLzGEUXWOjn2NOPQl6w3MZ1nslvAoJJzWHmB0-3D&ref=fdaweb.com). The agency is proposing a two-year implementation period, and it intends to reach out to affected stakeholders and state partners to answer questions about the recommended process for voluntarily making these marketing status changes.